Needham Gives a Hold Rating to Vericel (VCEL)

Needham analyst Chad Messer assigned a Hold rating to Vericel (VCELResearch Report) today. The company’s shares closed last Wednesday at $51.35.

According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.4% and a 41.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vericel with a $65.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $68.94 and a one-year low of $14.45. Currently, Vericel has an average volume of 425.9K.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2021, Heidi Hagen, a Director at VCEL bought 6,750 shares for a total of $34,860.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.